Celldex Therapeutics Inc. (CLDX)
Stock · NASDAQ · Health Care
$27.54as of 10/16/2026
Price chart
Active signals
CLDX Signal Track Record
How signals performed across all stocks →What CLDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | -0.8% | 43% | September 18, 2026 |
| Bollinger Band Breakout | 25 | -1.7% | 32% | August 5, 2026 |
| Bollinger Band Breakdown | 23 | +2.5% | 57% | September 11, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -0.9% | 47% | September 30, 2026 |
| Any 20-session window (baseline) | +0.6% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159),…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 198
- Website
- celldex.com/
Fundamentals
- 1-day range
- $27.65$28.85
- Market cap
- $3.26B
- P/E (trailing)
- —
- P/E (forward)
- -6.76
- EPS (trailing)
- $-4.36
- Dividend yield
- —
- Beta
- 1.00
- Avg. volume
- 1.35M
- Dividend pay date
- February 11, 2019
How Celldex Therapeutics Inc. Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Celldex Therapeutics Inc. Competitors
Chosen by industry and closest market cap.
- CLDXCelldex Therapeutics Inc.$27.53▼ 4.84%Market cap $3.26BP/E —$22.1$45.14
- NEOGNeogen Corporation Common Stock$11.81▼ 3.75%Market cap $2.46BP/E —$5.37$14.26
- NTLAIntellia Therapeutics Inc. Common Stock$11.42▲ 0.71%Market cap $1.57BP/E —$7.95$28.25
- NNNNAnbio Biotechnology Class A Ordinary Shares$3.13▼ 5.15%Market cap $1.40BP/E 46.55$3.52$44.73
- QDELQuidelOrtho Corporation Common Stock$12.91▼ 7.19%Market cap $1.11BP/E —$9.92$35.58
- ACHVAchieve Life Sciences Inc. Common Shares$6.38▼ 8.46%Market cap $672.42MP/E —$2.62$8.64
- ORKAOruka Therapeutics Inc. Common Stock$71.93▼ 2.63%Market cap $5.94BP/E —$24.88$115.52
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CLDX Celldex Therapeutics Inc. | $3.26B | — | $27.53 | ▼ 4.84% | $22.1$45.14 |
| NEOG Neogen Corporation Common Stock | $2.46B | — | $11.81 | ▼ 3.75% | $5.37$14.26 |
| NTLA Intellia Therapeutics Inc. Common Stock | $1.57B | — | $11.42 | ▲ 0.71% | $7.95$28.25 |
| NNNN Anbio Biotechnology Class A Ordinary Shares | $1.40B | 46.55 | $3.13 | ▼ 5.15% | $3.52$44.73 |
| QDEL QuidelOrtho Corporation Common Stock | $1.11B | — | $12.91 | ▼ 7.19% | $9.92$35.58 |
| ACHV Achieve Life Sciences Inc. Common Shares | $672.42M | — | $6.38 | ▼ 8.46% | $2.62$8.64 |
| ORKA Oruka Therapeutics Inc. Common Stock | $5.94B | — | $71.93 | ▼ 2.63% | $24.88$115.52 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Celldex Therapeutics: Trying To Put Its Troubled History Behind ItSeekingAlpha · 10/7/2026
- HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Targetbenzinga · 10/2/2026
- HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price TargetBenzinga · 10/2/2026
- Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?Yahoo · 9/23/2026
- The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteYahoo · 9/23/2026
- Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88Benzinga · 9/23/2026
- Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57Benzinga · 9/23/2026
- CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’Yahoo · 9/22/2026
- Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable ResponsesYahoo · 9/22/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 71.93M
- Total value held
- $2.20B
- Institutional holders
- 224
- Unknown8.56M
- Unknown5.84M
- Unknown5.37M
- Unknown3.75M
- Unknown3.23M
- Unknown2.96M
- Unknown2.80M
- Unknown2.70M
- Unknown2.09M
- Unknown1.79M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.